Open Reference PK/PD Model Sets Stage for Digital Twin Anaesthesia

Open-Source PK/PD Model for Anaesthesia: A New Technical Milestone

An open reference pharmacokinetic–pharmacodynamic (PK/PD) model for anaesthesia has been published, consolidating validated models for multiple drug classes into a single, mechanistically coupled framework. This model, described in detail by its authors (OpenAlex W7225695600, 2026-11-10), provides a mathematical and software blueprint for simulating the effects of hypnotics, opioids, neuromuscular blockers, vasoactive drugs, and volatile agents in adult patients. The model is open-source and intended as a research substrate, not a clinically validated device.

The significance of this development lies in its comprehensive approach: rather than modeling each anaesthetic drug in isolation, the framework integrates their interactions and links them to clinical signals such as the bispectral index (BIS), haemodynamics, nociception, respiratory safety, and neuromuscular blockade. This enables in-silico simulations that more closely reflect the realities of multi-drug anaesthesia in clinical practice.

Mechanism and Context: Digital Twins and Individualized Dosing

The model introduces a five-layer pharmacodynamic architecture, with each layer representing a key clinical endpoint—hypnosis, nociception, respiratory safety, haemodynamics, and neuromuscular blockade. Each drug's PK/PD profile is mapped onto these endpoints, and mechanistic couplings specify how drugs interact within and across layers. For example, opioids and hypnotics both influence hypnosis and nociception, while neuromuscular blockers and vasoactive agents have distinct but interacting effects on other layers.

Crucially, the framework incorporates covariates such as organ function, moving beyond anthropometric models that consider only weight or age. This allows for more individualized predictions, a key step towards the digital twin concept—virtual patient models that can be tailored to real individuals using their physiological data. The reference implementation demonstrated that individualizing the digital twin with just twenty minutes of monitoring data reduced median prediction error for BIS from 18.4% to 5.8% over a subsequent 15-minute window, though effect-site concentrations remained less precisely estimated.

While the model is designed for anaesthesia, its architecture and open-source nature make it adaptable to other multi-drug interventions, including complex regimens in psychedelic-assisted therapy where polypharmacy and individualized dosing are emerging challenges.

Policy and Research Implications for Psychedelic Therapies

This PK/PD framework, though not developed for psychedelics, sets a technical precedent for research on individualized, closed-loop dosing in psychedelic-assisted therapies. Current clinical trials in psychedelics (e.g., MDMA, psilocybin) typically use fixed or weight-adjusted dosing and rarely account for drug-drug interactions or dynamic physiological changes during sessions. As psychedelic protocols become more complex—potentially involving adjunctive medications for safety, efficacy, or side effect management—the need for robust, multi-drug PK/PD models will increase.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly expect quantitative systems pharmacology models to support drug development and individualized medicine. Open, reference-grade models like this one could accelerate the development of digital twin frameworks for psychedelic trials, supporting both safety monitoring and adaptive dosing strategies. However, clinical validation and regulatory acceptance remain significant hurdles.

One non-obvious implication is that in-silico test-bench frameworks can help de-risk early-stage psychedelic protocols by simulating polypharmacy scenarios before human trials, potentially identifying safety signals or optimal dosing strategies that would otherwise require costly and ethically complex studies.

Risks, Limitations, and Unknowns

The published model is not a clinically validated device and should not be used for patient care without further testing. Its predictions are limited by the accuracy of underlying PK/PD models, the quality of input data, and the assumptions embedded in mechanistic couplings. The authors note that while the model improves BIS prediction with individualized data, it does not substantially improve estimation of underlying effect-site concentrations—a limitation for real-time dosing control.

For psychedelic research, adapting this framework would require validated PK/PD models for the relevant compounds, which are currently lacking for most psychedelics and their combinations. There is also a risk that over-reliance on in-silico predictions could obscure unmodeled physiological or psychological effects, particularly in the context of consciousness-altering drugs.

Finally, the model's utility in diverse populations (e.g., older adults, those with comorbidities) will depend on the availability of covariate data and the robustness of the underlying models to real-world variability.

Future Directions: Towards Precision Polypharmacy in Psychedelic Trials

Open-source, multi-drug PK/PD frameworks represent a foundational step towards individualized, precision dosing in both anaesthesia and psychedelic-assisted therapies. As the field moves toward more complex, multi-agent protocols, such models will be essential for in-silico trial design, safety evaluation, and regulatory submission.

Key next steps include clinical validation of the model, expansion to additional drug classes (including psychedelics), and integration with real-time monitoring data to enable adaptive dosing and closed-loop control. Researchers and sponsors in the psychedelic field should consider engaging with these frameworks early, both to inform trial design and to anticipate future regulatory expectations for individualized, data-driven interventions.

How we research: This analysis was prepared by Dr. Alex R. Mendel, PhD (Neuroscience), and reviewed by Dr. Lisa S. Tran, MD (Clinical Pharmacology) on 2026-11-13. Primary source: OpenAlex W7225695600. Regulatory context sourced from FDA and EMA guidance documents.